08/24/2026
A meaningful step forward for the Rett syndrome community in Europe, and for progress in treating Rett around the world. 💜
The European Commission has granted marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients ages 5 years and older, making DAYBU the first and only treatment approved for Rett syndrome in the European Union.
The authorization applies across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. Pricing and reimbursement negotiations will now take place at the country level, so timing of access will vary.
We are encouraged to see an approved treatment option reach more of the global Rett community and will continue to share updates as they become available.
Read the full announcement from Acadia Pharmaceuticals: https://acadia.com/en-us/media/news-releases/european-commission-approves-daybu-trofinetide-as-the-first-and-only-treatment-for-neurobehavioral-symptoms-of-rett-syndrome-in-the-european-union